Table 3 Relation between high/low breast cancer necrosis signature (BCNS) score and clinico-pathologic features (TCGA cohort, n = 483).
Breast Cancer Necrosis Signature (BCNS) score | |||
|---|---|---|---|
Variable | High (n = 93) | Low (n = 390) | |
n(%) | n(%) | P-value† | |
ER status (IHC) | |||
Positive | 10 (10.9%) | 355 (92.2%) | < 0.001 |
Negative | 81 (88.0%) | 30 (7.8%) | |
PR status (IHC) | |||
Positive | 5 (5.6%) | 307 (79.7%) | < 0.001 |
Negative | 85 (94.4%) | 78 (20.3%) | |
HER2 (IHC) | |||
Negative | 87 (95.6%) | 308 (82.4%) | 0.002 |
Positive | 4 (4.4%) | 66 (17.6%) | |
Molecular subtypes (PAM50) | |||
Luminal A | 0 (0%) | 219 (56.2%) | < 0.001 |
Luminal B | 0 (0%) | 116 (29.7%) | |
HER2-enriched | 2 (2.2%) | 54 (13.8%) | |
Basal like | 91 (97.8%) | 1 (0.3%) | |
